Acotiamide Can Be Used as an Anti-Cognitive Disorder Agent in
Diseases Associated with Cognitive Dysfunction
Oznur Tufan Akarslan1, Mehmet Burak Ates2,
Gonca Sonmez3, Ozgur Ozdemir2, Burak Dik1,
Muhammed Hudai Culha3, Taha Hakan Uysal1,
Halis Oguz1 and Ayse Er1*
1Department
of Pharmacology and Toxicology, Faculty of Veterinary Medicine,
Selcuk University, Konya, Turkey; 2Department of
Pathology, Faculty of Veterinary Medicine, Selcuk University, Konya,
Turkey; 3Department of Genetics, Faculty of Veterinary
Medicine, Selcuk University, Konya, Turkey
The steady increase in average lifespan of humans and animals has made the
problem of aging-related cognitive impairment a significant issue. Alzheimer's
disease (AD) in humans is a degenerative brain disease characterized by the loss
of basic body functions due to neuronal damage, and canine cognitive dysfunction
observed in dogs is stated to resemble human AD. Acetylcholine esterase (AChE)
plays a role in the pathogenesis of the disease, and its inhibition prevents
AChE-induced Aβ aggregation. Other pathological factors, including oxidative
stress, inflammation and the Wnt pathway, also contribute to AD pathogenesis.
The use of AChE inhibitor (AChEI) is the most effective way among the several
available options for improving cholinergic symptoms. Although acotiamide is an
AChEI, there is currently no information regarding its use in AD; therefore,
this study aimed to examine the effects of acotiamide in an AD model for the
first time. A total of 26 mice were divided into 4 groups: control, sham,
Alzheimer and Alzheimer+Acotiamide. To create an experimental AD model,
streptozotocin was administered intracerebroventricularly. In addition,
acotiamide was administered intraperitoneally to the animals in the
Alzheimer+Acotiamide group. The study evaluated AChE, choline acetyltransferase,
β-secretase (BACE1), tumor necrosis factor-alpha, interleukin-10, α7nicotinic
acetylcholine receptor, glycogen synthase kinase3beta,
8-hydroxy-2-deoxyguanosine and glutathione parameters; along with the number of
neurons in the CA1 and CA3 regions, and the thickness in these areas. It can be
concluded from results that acotiamide could prevent neuroinflammation, reduce
AChE and BACE1 protein levels and may be effective in the treatment/prevention
of AD.
To Cite This Article:
Tufan-Akarslan
O, Ates MB, Sonmez G, Ozdemir O, Dik B, Culha MH, Uysal TH, Oguz H and Er A,
2025.
Acotiamide can be used as an anti-cognitive disorder agent in diseases
associated with cognitive dysfunction.
Pak Vet J.
http://dx.doi.org/10.29261/pakvetj/2025.319